Mylan CEO promises Neulasta biosimilar will offer "significant savings" for patients - (CBS News via NewsPoints Desk)

  • Mylan CEO Heather Bresch said the availability of the company's biosimilar of Neulasta will result in "significant savings" for patients, CBS News reported Tuesday.

  • Mylan recently won FDA approval to market its therapy, marking the first authorisation of a biosimilar of Neulasta.

  • "We'll be launching our biosimilar to Neulasta in the coming weeks at a significant reduction," Bresch stated, adding "double-digits reduction."

  • Bresch separately expressed support for plans unveiled by the administration of US President Donald Trump to lower drug prices.

  • "When we're talking just about pharmaceuticals, I think that as the president has talked about a blueprint for how do we make it market-based and how do we bring transparency and I think that that would bring tremendous savings to patients," Bresch remarked.

  • Mylan has previously faced criticism over decisions to dramatically raise the price of EpiPen.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>    

To read more NewsPoints articles, click here.